Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

Shares of TTNP stock opened at $3.48 on Tuesday. The firm has a market cap of $3.18 million, a P/E ratio of -0.67 and a beta of 1.19. The business’s 50 day moving average price is $3.66 and its 200-day moving average price is $4.02. Titan Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $14.80.

Titan Pharmaceuticals (NASDAQ:TTNP) last issued its quarterly earnings data on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) EPS for the quarter.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.